Recombinant Canine CTLA-4 Fc Chimera, CF

Catalog #: 10954-CT Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
10954-CT-100

Recombinant Canine CTLA‑4 Fc Chimera Protein Bioactivity.

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Canine CTLA-4 Fc Chimera, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. Linsley, P.S. et al. (1991) J. Exp. Med. 174:561. The ED₅₀ for this effect is 30.0-300 ng/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived canine CTLA-4 protein
Lys36-Asp161

Accession #

NP_001003106.1

N-terminal Sequence
Analysis

Lys36

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

40 kDa

SDS-PAGE

48-60 kDa, under reducing conditions.

Product Datasheets

10954-CT

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10954-CT

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Canine CTLA-4 Fc Chimera Protein (Catalog # 10954-CT) inhibits IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. The ED₅₀ for this effect is 30.0-300 ng/mL

SDS-PAGE

View Larger

2 μg/lane of Recombinant Canine CTLA-4 Fc Chimera Protein (Catalog # 10954-CT) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 48-60 kDa and 100-120 kDa, respectively.

Reconstitution Calculator

Background: CTLA-4

CTLA-4 (cytotoxic T-lymphocyte-4, designated CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily (1, 2). Canine CTLA-4 cDNA A encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence.Within the ECD, canine CTLA-4 shares 84%, 69%, and 71% aa sequence identity with human, mouse and rat CTLA-4 respectively. CD28, which is structurally related to CTLA-4, is constitutively expressed on naïve T cells and promotes T cell activation when engaged by B7-2 on antigen-presenting cells (APC) within the immunological synapse (IS) (1, 3, 4). In contrast, CTLA-4 is recruited from intracellular vesicles to the IS beginning 1, 2 days after T cell activation (2, 3, 4). It forms a linear lattice with B7‑1 on APC, inducing negative regulatory signals and ending T cell activation (5). Abatacept, a therapeutic human CTLA-4-Ig fusion protein (trade name Orencia), competes with CD28 for B7-1 and B7-2 binding and has been used to antagonize T cell activation in autoimmune conditions and to enhance transplant survival (6). Mice deleted for CTLA-4 show no abnormalities until after birth, but then develop lethal autoimmune reactions due to continued T cell activation and poor control by regulatory T cells, which constitutively express CTLA-4 in wild-type mice and humans (7‑9).

References

Harper, K. et al. (1991) J. Immunol. 147:1037.
Teft, W.A. et al. (2006) Annu. Rev. Immunol. 24:65.
Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
Jansson, A. et al. (2005) J. Immunol 175:1575.
Darlington, P.J. et al. (2005) J. Immunol. 175:996.
Platt, A.M. et al. (2010) J. Immunol. 185:1558.
Wing, K. et al. (2008) Science 322:271.
Friedline, R.H. et al. (2009) J. Exp. Med. 206:421.
Jain, N. et al. (2010) Proc. Natl. Acad. Sci. U.S.A. 107:1524.

Long Name

Cytotoxic T-lymphocyte-associated Molecule 4

Entrez Gene IDs

1493 (Human); 12477 (Mouse); 403696 (Canine); 102115124 (Cynomolgus Monkey)

Alternate Names

CD; CD152 antigen; CD152; CD152IDDM12; CD28; celiac disease 3; CELIAC3; CTLA4; CTLA-4; cytotoxic T-lymphocyte antigen 4; cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated protein 4; cytotoxic T-lymphocyte-associated serine esterase-4; GRD4; GSE; ICOS; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4